Medical DevicesLast reviewed May 2026

Combination Product(Combination Product)

A therapeutic product combining two or more regulated components (drug, device, biologic) with a primary mode of action determining the lead FDA center.

Usage Examples

The RFD confirmed CDRH as the lead center for the drug-eluting device based on the device PMoA.
Combination product GMP was implemented per 21 CFR Part 4, streamlining both drug and device requirements.
Postmarket safety reports were split between MedWatch (drug component) and MDR (device component).

What is Combination Product?

A combination product is a therapeutic or diagnostic product comprised of two or more regulated components — drug/device, drug/biologic, device/biologic, or drug/device/biologic — as defined in 21 CFR 3.2(e). Examples include prefilled syringes (drug + device), drug-eluting stents (device + drug), transdermal patches (drug + device), and gene therapies delivered by specialized devices (biologic + device).

Combination products are regulated by FDA's Office of Combination Products (OCP), which assigns a lead center (CDER, CBER, or CDRH) based on the Primary Mode of Action (PMoA) — the single mode of action that provides the most important therapeutic effect. The lead center conducts review, with consulting input from the non-lead centers as needed. Sponsors can request designation through a Request for Designation (RFD) when PMoA is unclear.

Combination products face unique regulatory challenges: applicable GMP requirements come from both drug (21 CFR 211) and device (21 CFR 820) frameworks, typically implemented through 21 CFR Part 4. Postmarket safety reporting follows MedWatch for the drug component and MDR for the device component. Combination product labeling must address both components consistently.

Regulatory Context

This term appears most often in medical devices workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 3, 21 CFR 4, FDCA SECTION 503G.

FDA CDRHEMAHealth Canada

When This Matters

The RFD confirmed CDRH as the lead center for the drug-eluting device based on the device PMoA.
Combination product GMP was implemented per 21 CFR Part 4, streamlining both drug and device requirements.
Postmarket safety reports were split between MedWatch (drug component) and MDR (device component).

Common Mistakes

Using drug-only submission assumptions for device regulatory pathways.
Ignoring post-market obligations in pre-market planning.
Weak predicate and classification rationale in dossier narratives.

Related Regulations

21 CFR 321 CFR 4FDCA SECTION 503G

Frequently Asked Questions

Primary Mode of Action (PMoA) — the single mode that provides the most important therapeutic effect. Drug PMoA → CDER (or CBER for biologics). Device PMoA → CDRH. When PMoA is unclear or disputed, sponsors can file a Request for Designation (RFD) to obtain a binding determination.

No. A combination product is approved through a single submission to the lead center. CDER approves an NDA that includes the device component's data; CDRH approves a 510(k) or PMA that includes the drug component's data. Separate clearances are not required, but the review involves consulting input from the non-lead center.

21 CFR Part 4 provides a streamlined approach: manufacturers must comply with either drug GMP (21 CFR 211) or device GMP (21 CFR 820) as the primary framework, plus specified elements from the other framework relevant to their product's unique combination-product features.